<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16766">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078609</url>
  </required_header>
  <id_info>
    <org_study_id>CLGH447X2102</org_study_id>
    <secondary_id>2013-003756-20</secondary_id>
    <nct_id>NCT02078609</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>France: Agence Nationale de Securité du médicament</authority>
    <authority>Germany: The Federal Institute for Drugs and Medical Devices (BfArM)</authority>
    <authority>Italy: Ministry of Labor, Health &amp; Social Affairs, Department of Innovation</authority>
    <authority>Netherlands: Dutch Healthcare Inspectorate (IGZ)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and preliminary efficacy of escalating doses of LGH447 in
      AML and MDS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLTs)</measure>
    <time_frame>30 days post study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency and characteristics of dose limiting toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with the type, frequency, and severity of adverse events (AEs) as a measure of safety and tolerability</measure>
    <time_frame>weekly to bi-weekly up to 1.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Includes changes in hematology and blood chemistry values, assessments of physical examinations, vital signs, and electrocardiograms (ECGs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters including but not limited to Cmax, Cmin, AUCinf, AUCtlast, AUCtau and T1/2</measure>
    <time_frame>days 1, 2, 15, 16, 29, 30, 44, 57, and approximately monthly up to 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>LGH447 plasma concentrations and basic PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes between pre- and post-treatment levels of pS6RP and p4EBP1 in bone marrow aspirates and p4EBP1 in peripheral blood</measure>
    <time_frame>screening, days 1 and 29 up to 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess pharmacodynamic effects of LGH447</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre- and post-treatment levels of leukemic blasts in the peripheral blood and bone marrow and normal cells in the peripheral blood</measure>
    <time_frame>approximately monthly up to 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess clinical response associated with LGH447 which includes Complete Response (CR), Complere Response in incomplete blood count (CRi), Partial Response (PR), Best Overall Response (BOR), Duration of Response (DoR), Time to Progression (TTP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pre- and post-treatment levels of leukemic blasts in the peripheral blood and bone marrow and normal cells in the peripheral blood</measure>
    <time_frame>approximately monthly up to 1.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess clinical response associated with LGH447 which includes Complete Response (CR), bone marror CR, Partial Response (PR), Hematologic response-Erythroid, platelet, neutrophil (HI-E,P, N), Best Overall Response (BOR), Duration of Response (DoR), Time to Progression (TTP), Progression Free Survival (PFS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>AML and High Risk MDS</condition>
  <arm_group>
    <arm_group_label>LGH447</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study dosed with LGH447</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGH447</intervention_name>
    <arm_group_label>LGH447</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Relapsed/refractory AML following no more than 2 prior therapies or in AML patient
             for whom no effective therapy exists; or high and very high risk MDS

          -  For AML patients, peripheral blast counts &lt; 50,000 blasts/mm3

          -  For MDS patients;

               -  Platelet count &gt; 25,000/mm3

               -  Neutrophils &gt; 500/mm3

               -  Blood transfusions are allowed to maintain clinically adequate hemoglobin and
                  hematocrit levels

          -  Patients with active central nervous system (CNS) disease are eligible to participate
             and may be treated concurrently with intrathecal (or intra Ommaya) chemotherapy

          -  Patients who are maintained on prophylactic antibiotics are eligible to participate
             as long as agents comply with the list of approved concomitant medications

             -≥ 18 year old

          -  Performance status ≤ 2

          -  Meet other lab criteria

        Exclusion criteria:

          -  Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and
             toxin immunoconjugates) or any experimental therapy within 7 days or 5 half-lives,
             whichever is longer, before the first dose of LGH447

          -  Radiotherapy with a wide field of radiation within 28 days or radiotherapy with a
             limited field of radiation for palliation within 7 days of the first dose of LGH447

          -  Patients who received CNS irradiation for meningeal leukemia, except if radiotherapy
             occurred &gt; 3 months previously

          -  Major surgery within 4 weeks before the first dose of LGH447

          -  Ongoing therapy with corticosteroids greater than 10 mg of prednisone or its
             equivalent per day. Inhaled and topical steroids are permitted

          -  Patients who are currently receiving hydroxyurea to control peripheral blood leukemic
             blasts and cannot be discontinued for at least 48 hours prior to obtaining PD
             biomarkers at screening/baseline and during the study

          -  Patients who are currently receiving treatment with prohibited medication and that
             cannot be discontinued at least one week prior to the start of treatment with LGH447

          -  Active infection requiring systemic therapy or other severe infection, including
             pneumonia, within 2 weeks before the first dose of LGH447.

          -  Known human immunodeficiency virus (HIV) positive

          -  Corrected QT interval (QTc) of &gt; 450 milliseconds (ms) in males and &gt; 470
             milliseconds (ms) in females on baseline electrocardiogram (ECG) (using corrected QT
             interval using Fridericia [QTcF] or local standards).

          -  Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias,
             congestive heart failure, angina, or myocardial infarction within the past 6 months—

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center Onc Dept</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina P. Willbee</last_name>
      <phone>734-936-3879</phone>
      <email>tpelton@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Dale Bixby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML,</keyword>
  <keyword>MDS,</keyword>
  <keyword>PIM,</keyword>
  <keyword>LGH447,</keyword>
  <keyword>acute myelod leukemia,</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
